Fundus-oriented perimetry (FOP) was used to evaluate the effectiveness of different-sized bright and dark stimuli in detecting and quantitatively measuring angioscotoma. The foveolas and optic disks of digitized fundus images were aligned with their psychophysical counterparts to construct individual grids of perimetric stimuli. Each grid included a linear… (More)
Vorapaxar, a novel antiplatelet agent in advanced clinical development for the prevention and treatment of atherothrombotic disease, is a potent, orally bioavailable thrombin receptor antagonist selective for the protease-activated receptor 1 (PAR-1). Since race/ethnicity may affect the safety, efficacy and dosage of drugs, this study was conducted to… (More)
To determine whether impaired renal function alters the pharmacokinetics (PK) of vorapaxar or its ability to inhibit thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. This was an open-label study in which 8 patients with end-stage renal disease (ESRD) on hemodialysis and 7 matched (based on age, gender, weight, and height) healthy… (More)
Aspect ratio and electrophoretic mobility data for amphibole particles reveal that short fibers and blocky cleavage fragments have a smaller net charge than highly elongated particles. Asbestos fibers and cleavage fragments of the same dimensions exhibit the same net negative surface charge but positively charged ends and negatively charged lateral surfaces.
To determine whether hepatic impairment has an effect on the pharmacokinetics (PK) of vorapaxar or M20, its main pharmacologically active metabolite. This was an open-label study in which a single 40-mg oral dose of vorapaxar was administered to patients with mild (n = 6), moderate (n = 6), and severe (n = 4) hepatic impairment and healthy controls (n = 16)… (More)